ArticleBMC musculoskeletal disorders2025
Growth factor and cell content in Platelet-Rich Plasma (PRP), Leukocyte- and Platelet-Rich Plasma (L-PRP), Platelet-Rich Fibrin (PRF) in patients with long bone defects from combat injuries.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and Radiographic Evaluation of Plasma Rich in Growth Factors (PRGF) for Alveolar Ridge Preservation in the Anterior Maxilla.Journal of functional biomaterials · 2026Article
- Design Strategies to Target Joint Resident Mesenchymal Stem Cells for Osteochondral Regeneration.Cells · 2026Review
- Activated platelet rich plasma modulates the proliferation, apoptosis and matrix synthesis driven by growth factors in osteoarthritic chondrocytes: anFrontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn contemporary regenerative medicine, platelet concentrates (PCs) are actively used as a promising method to support the regenerative process. However, the lack of standardized preparation protocols and the selection of PC types limits their broad clinical implementation, particularly in patients with non-unions or bone defects. Therefore, the aim of this study was to determine the concentration of platelets, leukocytes, and growth factors such as vascular endothelial growth factor (VEGF-A), transforming growth factor beta (TGF-β1), platelet-derived growth factor (PDGF-BB) in three types of PC, such as platelet-rich plasma (PRP), leukocyte- and platelet-rich plasma (L-PRP), platelet-rich fibrin (PRF) using a single donor model in patients with large bone defects after combat trauma compared to healthy individuals.
methodsBlood for PRP, L-PRP and PRF was collected from 30 participants. 19 healthy volunteers and 11 patients with long bone defects after combat injuries. For the production of three types of PC, 15 ml of blood was taken from each participant. The cellular composition was determined using an automated hematological analyzer. The concentration of growth factors VEGF-A, TGF-β1, PDGF-BB was determined by ELISA.
resultsDifferences in cellular composition and growth factor concentration between PC types were identified in all study participants. The concentration of platelets in PCs was distributed as follows: L-PRP > PRP > PRF; however, this did not affect the concentration of growth factors. The concentration of growth factors in PCs from patients with bone defects did not differ from that of healthy individuals. In patients with bone defects, it was not possible to achieve an enrichment of leukocyte concentration in L-PRP compared to the baseline level of whole blood; however, this parameter did not differ from that of healthy individuals.
conclusionsGrowth factor concentrations were similar in patients and healthy individuals, but patients had differences in L-PRP leukocyte enrichment and lower platelet recovery in PRF. This study highlights the need to consider platelet concentrate characteristics when selecting products for regenerative therapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.